The Extracellular Matrix and the Growth and Survival of Tumors

  • Yves A. DeClerck
Part of the Cancer Drug Discovery and Development book series (CDD&D)


The role of the extracellular matrix (ECM) in the tumor microenvironment extends well beyond the formation of a barrier against tumor invasion. Through a combination of physical forces and chemical signals generated upon contact between cells and ECM proteins, the ECM exerts a control on the proliferation and survival of cancer cells, which were previously considered to be solely affected by genetic alterations. The interaction between tumor cells and the ECM is also a dynamic one that changes upon modification of the ECM by proteases produced by tumor cells and by normal cells in the tumor microenvironment. These proteases modify the ECM generating cryptic epitopes, producing proteolytic fragments that are biologically active and releasing growth factors and cytokines that are trapped in the ECM. Our knowledge of the mechanisms by which the ECM controls cancer cells has significantly improved over the last 10 years and is now leading toward clinical trials testing agents disrupting tumor cell–ECM interaction.


Collagen Type Zoledronic Acid Focal Adhesion Kinase Proteolytic Modification Proteolytic Fragment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aplin AE, Howe AK, Juliano R (1999) Cell adhesion molecules, signal transduction and cell growth [see comments]. Curr Opin Cell Biol 11:737–744PubMedCrossRefGoogle Scholar
  2. Aplin AE, Juliano RL (1999) Integrin and cytoskeletal regulation of growth factor signaling to the MAP kinase pathway. J Cell Sci 112(Pt 5):695–706PubMedGoogle Scholar
  3. Armstrong LC, Bornstein P (2003) Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 22:63–71PubMedCrossRefGoogle Scholar
  4. Avvisato CL et al (2007) Mechanical force modulates global gene expression and beta-catenin signaling in colon cancer cells. J Cell Sci 120:2672–2682PubMedCrossRefGoogle Scholar
  5. Bergers G et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737–744PubMedCrossRefGoogle Scholar
  6. Bornstein P, Sage EH (2002) Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 14:608–616PubMedCrossRefGoogle Scholar
  7. Butcher DT, Alliston T, Weaver VM (2009) A tense situation: forcing tumour progression. Nat Rev Cancer 9:108–122PubMedCrossRefGoogle Scholar
  8. Cao Y et al (1996) Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 271:29461–29467PubMedCrossRefGoogle Scholar
  9. Chang JH et al (2005) Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type XVIII collagen. FEBS Lett 579:3601–3606PubMedCrossRefGoogle Scholar
  10. Chen CS et al (1997) Geometric control of cell life and death. Science 276:1425–1428PubMedCrossRefGoogle Scholar
  11. Clezardin P (2002) The antitumor potential of bisphosphonates. Semin Oncol 29:33–42PubMedGoogle Scholar
  12. Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 4(9 Suppl):14–27CrossRefGoogle Scholar
  13. Colorado PC et al (2000) Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 60:2520–2526PubMedGoogle Scholar
  14. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387–2392PubMedCrossRefGoogle Scholar
  15. Coussens LM et al (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103:481–490PubMedCrossRefGoogle Scholar
  16. Craig DH, Haimovich B, Basson MD (2007) Alpha-actinin-1 phosphorylation modulates pressure-induced colon cancer cell adhesion through regulation of focal adhesion kinase-Src interaction. Am J Physiol Cell Physiol 293:C1862–C1874PubMedCrossRefGoogle Scholar
  17. Dahl KN, Ribeiro AJ, Lammerding J (2008) Nuclear shape, mechanics, and mechanotransduction. Circ Res 102:1307–1318PubMedCrossRefGoogle Scholar
  18. Franzen CA et al (2009) Matrix protein CCN1 is critical for prostate carcinoma cell proliferation and TRAIL-induced apoptosis. Mol Cancer Res 7:1045–1055PubMedCrossRefGoogle Scholar
  19. Garra BS (2007) Imaging and estimation of tissue elasticity by ultrasound. Ultrasound Q 23:255–268PubMedCrossRefGoogle Scholar
  20. Gieni RS, Hendzel MJ (2008) Mechanotransduction from the ECM to the genome: are the pieces now in place? J Cell Biochem 104:1964–1987PubMedCrossRefGoogle Scholar
  21. Goldoni S, Iozzo RV (2008) Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 123:2473–2479PubMedCrossRefGoogle Scholar
  22. Gu J et al (2002) Laminin-10/11 and fibronectin differentially prevent apoptosis induced by serum removal via Phosphatidylinositol 3-KInase/AKT and MEK1/ERK-dependent pathways. J Biol Chem 277:19922–19928PubMedCrossRefGoogle Scholar
  23. Guise TA (2000) Molecular mechanisms of osteolytic bone metastases. Cancer 88:2892–2898PubMedCrossRefGoogle Scholar
  24. Guise TA, Chirgwin JM (2003) Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res S32–S38Google Scholar
  25. Guo W, Giancotti FG (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5:816–826PubMedCrossRefGoogle Scholar
  26. Han SW, Roman J (2006) Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa B. Oncogene 25:4341–4349PubMedCrossRefGoogle Scholar
  27. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedCrossRefGoogle Scholar
  28. He GA et al (2003) Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth. Biochem Biophys Res Commun 312:801–805PubMedCrossRefGoogle Scholar
  29. Henriet P et al (2000) Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci U S A 97:10026–10031PubMedCrossRefGoogle Scholar
  30. Hotary KB et al (2003) Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114:33–45PubMedCrossRefGoogle Scholar
  31. Houghton AM et al (2006) Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res 66:6149–6155PubMedCrossRefGoogle Scholar
  32. Huang S, Chen CS, Ingber DE (1998) Control of cyclin D1, p27(Kip1), and cell cycle progression in human capillary endothelial cells by cell shape and cytoskeletal tension [In Process Citation]. Mol Biol Cell 9:3179–3193PubMedGoogle Scholar
  33. Iruela-Arispe ML et al (1999) Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100:1423–1431PubMedCrossRefGoogle Scholar
  34. Juliano R (1996) Cooperation between soluble factors and integrin-mediated cell anchorage in the control of cell growth and differentiation. Bioessays 18:911–917PubMedCrossRefGoogle Scholar
  35. Kamphaus GD et al (2000) Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 275:1209–1215PubMedCrossRefGoogle Scholar
  36. Kawaguchi T et al (2006) The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res 66:11331–11340PubMedCrossRefGoogle Scholar
  37. Kim WH et al (1999) Laminin-1-adherent cancer cells show increased proliferation and decreased apoptosis in vivo. Anticancer Res 19:3067–3071PubMedGoogle Scholar
  38. Kojima T, Azar DT, Chang JH (2008) Neostatin-7 regulates bFGF-induced corneal lymphangiogenesis. FEBS Lett 582:2515–2520PubMedCrossRefGoogle Scholar
  39. Koyama H et al (1996) Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 87:1069–1078PubMedCrossRefGoogle Scholar
  40. Kulke MH et al (2006) Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24:3555–3561PubMedCrossRefGoogle Scholar
  41. Kurenova E et al (2004) Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Mol Cell Biol 24:4361–4371PubMedCrossRefGoogle Scholar
  42. Kurup A et al (2006) Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann Oncol 17:97–103PubMedCrossRefGoogle Scholar
  43. Larsen M et al (2006) The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol 18:463–471PubMedCrossRefGoogle Scholar
  44. Lee NV et al (2006) ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J 25:5270–5283PubMedCrossRefGoogle Scholar
  45. Linden RA, Halpern EJ (2007) Advances in transrectal ultrasound imaging of the prostate. Semin Ultrasound CT MR 28:249–257PubMedCrossRefGoogle Scholar
  46. Lipton A (2003) Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs 8:469–488PubMedCrossRefGoogle Scholar
  47. Lopez JI, Mouw JK, Weaver VM (2008) Biomechanical regulation of cell orientation and fate. Oncogene 27:6981–6993PubMedCrossRefGoogle Scholar
  48. Lopez-Otin C, Matrisian LM (2007) Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7:800–808PubMedCrossRefGoogle Scholar
  49. MacDonald TJ et al (2008) Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 26:919–924PubMedCrossRefGoogle Scholar
  50. Maeshima Y et al (2002) Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295:140–143PubMedCrossRefGoogle Scholar
  51. Magnon C et al (2005) Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins. Cancer Res 65:4353–4361PubMedCrossRefGoogle Scholar
  52. Marastoni S et al (2008) Extracellular matrix: a matter of life and death. Connect Tissue Res 49:203–206PubMedCrossRefGoogle Scholar
  53. Michaelson MD, Smith MR (2005) Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 23:8219–8224PubMedCrossRefGoogle Scholar
  54. Miyazaki T et al (2004) Functional role of death-associated protein 3 (DAP3) in anoikis. J Biol Chem 279:44667–44672PubMedCrossRefGoogle Scholar
  55. Mongiat M et al (2007) Regulation of the extrinsic apoptotic pathway by the extracellular matrix glycoprotein EMILIN2. Mol Cell Biol 27:7176–7187PubMedCrossRefGoogle Scholar
  56. Moschos SJ et al (2007) Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res 17:193–200PubMedCrossRefGoogle Scholar
  57. Mundel TM, Kalluri R (2007) Type IV collagen-derived angiogenesis inhibitors. Microvasc Res 74:85–89PubMedCrossRefGoogle Scholar
  58. Nyberg P et al (2008) Characterization of the anti-angiogenic properties of arresten, an alpha1beta1 integrin-dependent collagen-derived tumor suppressor. Exp Cell Res 314:3292–3305PubMedCrossRefGoogle Scholar
  59. O’Reilly MS et al (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315–328PubMedCrossRefGoogle Scholar
  60. O’Reilly MS et al (1999) Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 274:29568–29571PubMedCrossRefGoogle Scholar
  61. Overall CM, Kleifeld O (2006) Tumour microenvironment – opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6:227–239PubMedCrossRefGoogle Scholar
  62. Paszek MJ, Weaver VM (2004) The tension mounts: mechanics meets morphogenesis and malignancy. J Mammary Gland Biol Neoplasia 9:325–342PubMedCrossRefGoogle Scholar
  63. Payne SL et al (2005) Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res 65:11429–11436PubMedCrossRefGoogle Scholar
  64. Payne SL, Hendrix MJ, Kirschmann DA (2007) Paradoxical roles for lysyl oxidases in cancer – a prospect. J Cell Biochem 101:1338–1354PubMedCrossRefGoogle Scholar
  65. Pozzi A, LeVine WF, Gardner HA (2002) Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 21:272–281PubMedCrossRefGoogle Scholar
  66. Puolakkainen PA et al (2004) Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2:215–224PubMedGoogle Scholar
  67. Reardon DA et al (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26:5610–5617PubMedCrossRefGoogle Scholar
  68. Reddig PJ, Juliano RL (2005) Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev 24:425–439PubMedCrossRefGoogle Scholar
  69. Reginato MJ et al (2003) Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 5:733–740PubMedCrossRefGoogle Scholar
  70. Rehn M et al (2001) Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A 98:1024–1029PubMedCrossRefGoogle Scholar
  71. Reynolds AR et al (2009) Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 15:392–400PubMedCrossRefGoogle Scholar
  72. Ricart AD et al (2008) Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 14:7924–7929PubMedCrossRefGoogle Scholar
  73. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655–1664PubMedCrossRefGoogle Scholar
  74. Sid B et al (2004) Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth. Crit Rev Oncol Hematol 49:245–258PubMedCrossRefGoogle Scholar
  75. Siegmann KC et al (2009) Diagnostic value of MR elastography in addition to contrast-enhanced MR imaging of the breast-initial clinical results. Eur Radiol 20:318–325PubMedCrossRefGoogle Scholar
  76. Tlsty TD, Coussens LM (2006) Tumor stroma and regulation of cancer development. Annu Rev Pathol 1:119–150PubMedCrossRefGoogle Scholar
  77. Tran KT, Lamb P, Deng JS (2005) Matrikines and matricryptins: implications for cutaneous cancers and skin repair. J Dermatol Sci 40:11–20PubMedCrossRefGoogle Scholar
  78. Trikha M et al (2002) Role of beta 3 integrins in human melanoma growth and survival. Int J Cancer 101:156–167PubMedCrossRefGoogle Scholar
  79. Tse ZT et al (2009) Magnetic resonance elastography hardware design: a survey. Proc Inst Mech Eng H 223:497–514PubMedGoogle Scholar
  80. Vlodavsky I et al (2007) Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 13:2057–2073PubMedCrossRefGoogle Scholar
  81. Wall SJ et al (2005) Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen. J Biol Chem 280: 40187–40194PubMedCrossRefGoogle Scholar
  82. Wall SJ, Zhong ZD, DeClerck YA (2007) The cyclin-dependent kinase inhibitors p15INK4B and p21CIP1 are critical regulators of fibrillar collagen-induced tumor cell cycle arrest. J Biol Chem 282:24471–24476PubMedCrossRefGoogle Scholar
  83. Watanabe K et al (2000) Interaction with heparin and matrix metalloproteinase 2 cleavage expose a cryptic anti-adhesive site of fibronectin. Biochemistry 39:7138–7144PubMedCrossRefGoogle Scholar
  84. Weaver VM et al (1997) Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137:231–245PubMedCrossRefGoogle Scholar
  85. Wen W et al (1999) The generation of endostatin is mediated by elastase. Cancer Res 59:6052–6056PubMedGoogle Scholar
  86. Wolf K et al (2003) Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 160:267–277PubMedCrossRefGoogle Scholar
  87. Wolfe JN (1976) Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 37:2486–2492PubMedCrossRefGoogle Scholar
  88. Xie L et al (2008) Basement membrane derived fibulin-1 and fibulin-5 function as angiogenesis inhibitors and suppress tumor growth. Exp Biol Med (Maywood) 233:155–162CrossRefGoogle Scholar
  89. Xu J et al (2001) Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154:1069–1079PubMedCrossRefGoogle Scholar
  90. Yin JJ et al (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197–206PubMedCrossRefGoogle Scholar
  91. Zutter MM (2007) Integrin-mediated adhesion: tipping the balance between chemosensitivity and chemoresistance. Adv Exp Med Biol 608:87–100PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Departments of Pediatrics and Biochemistry and Molecular BiologyUniversity of Southern California and The Saban Research Institute of Childrens Hospital Los AngelesLos AngelesUSA

Personalised recommendations